UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 20, 2005
LIFELINE
THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Colorado |
000-30489 |
84-1097796 | |||
|---|---|---|---|---|---|
| (State or other jurisdiction | (Commission File Number) | (IRS Employer Identification No.) | |||
| of incorporation) | |||||
6400 South
Fiddler's Green Circle, Suite 1750, Englewood, CO 80111
(Address of principal
executive offices) (Zip Code)
Registrant’s telephone number, including area code: (720) 488-1711
N/A
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01. Regulation FD.
On July 20, 2005, Lifeline Therapeutics, Inc. issued a press release entitled “Protandim to be Available at General Nutrition Center (GNC) Stores.” A copy of the press release is attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this report shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing.
ITEM 9.01 Financial Statements and Exhibits.
(c) Exhibits
| Exhibit Number | Description of Exhibit | ||
99.1 |
Press Release, dated July 20, 2005 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: July 26, 2005
LIFELINE
THERAPEUTICS, INC. |
2
Exhibit 99.1
| Media Contacts: | |||
| LIFELINE THERAPEUTICS, INC. | OGILVY PUBLIC RELATIONS | ||
| Paul Myhill | WORLDWIDE | ||
| paulm@protandim.com | Aliza Rothman | ||
| 720.488.1711, ext. 16 | aliza.rothman@ogilvypr.com | ||
| 303.634.2672 |
Protandim to be Available at General Nutrition Center (GNC) Stores
DENVER, COLORADO, July 20, 2005 — Lifeline Therapeutics, Inc. (OTCBB: LFLT) today announced that its Protandim™ dietary supplement, an antioxidant therapy, will be available next month at thousands of General Nutrition Center (GNC) stores.
The initial order comes on the heels of Protandim being featured on ABC News’ PrimeTime Live.
Amy Cone, director of marketing for Lifeline stated, “We are thrilled to expand Protandim’s distribution and make it more accessible to consumers across the nation. We’re also proud to be working with the world’s largest and most reputable retailer of nutritional supplements.”
Interested customers are able to place their name on a notification list at any of GNC’s 4,500 retail stores in order to be alerted when Protandim hits shelves.
ABOUT LIFELINE THERAPEUTICS
Lifeline Therapeutics, Inc. is a publicly-traded company (OTCBB: LFLT) based in Denver, Colorado that manufactures and sells Protandim.
Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable common law. These statements involve known and unknown risks and uncertainties that may cause the Company’s actual results or outcomes to be materially different from those anticipated and discussed herein. Further, the Company operates in industries where securities values may be volatile and may be influenced by regulatory and other factors beyond the Company’s control. Other important factors that the Company believes might cause such differences include the Company’s limited cash flow and the rapid development of technology, lack of liquidity for the Company’s common stock, working capital shortages, the length of time for scientific advances to reach the market (if they ever reach the market), among other risks. In assessing forward-looking statements contained herein, readers are urged to carefully read all cautionary statements contained in the Company’s filings with the Securities and Exchange Commission.
# # #